These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 451263)

  • 21. Effect of D-penicillamine on liver fibrosis and inflammation in Wilson disease.
    Kazemi K; Geramizadeh B; Nikeghbalian S; Salahi H; Bahador A; Reza Nejatollahi SM; Dehghani SM; Dehghani M; Kakaei F; Malek-Hosseini SA
    Exp Clin Transplant; 2008 Dec; 6(4):261-3. PubMed ID: 19338486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methods for assaying D-penicillamine in a clinical setting.
    Crawhall JC
    Clin Invest Med; 1984; 7(1):31-4. PubMed ID: 6723121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Copper and taste sensitivity.
    Nutr Rev; 1968 Jun; 26(6):175-7. PubMed ID: 4874926
    [No Abstract]   [Full Text] [Related]  

  • 24. [Therapeutic problems during D-penicillamine treatment of patients with cystine calculi].
    Wenzl H; Kludas M
    Munch Med Wochenschr; 1970 Nov; 112(48):2187-90. PubMed ID: 5536878
    [No Abstract]   [Full Text] [Related]  

  • 25. Copper chelating agents. A comparison of cupruretic responses to various tetramines and D-penicillamine.
    Borthwick TR; Benson GD; Schugar HJ
    J Lab Clin Med; 1980 Apr; 95(4):575-80. PubMed ID: 7359013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease.
    Siafakas CG; Jonas MM; Alexander S; Herrin J; Furuta GT
    Am J Gastroenterol; 1998 Dec; 93(12):2544-6. PubMed ID: 9860423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Liver copper determination in long-term treatment of Wilson's disease with D-penicillamine].
    Lange J; Brandt G
    Med Welt; 1981 Jan; 32(3):109-10. PubMed ID: 7207132
    [No Abstract]   [Full Text] [Related]  

  • 28. [Biochemical bases and therapeutic possibilities of K. Wilson's hepatolenticular degeneration].
    Grau-Veciana JM; Barraquer-Bordas L
    Arch Neurobiol (Madr); 1967; 30(3):251-74. PubMed ID: 4970136
    [No Abstract]   [Full Text] [Related]  

  • 29. [Anatomo-clinical study of a case of Wilson's disease treated with chelating agents for 5 years].
    Boudin G; Pépin B; Milhaud M; Jérome H; Pacilly A
    Rev Neurol (Paris); 1968 Jan; 118(1):27-35. PubMed ID: 5697565
    [No Abstract]   [Full Text] [Related]  

  • 30. Patient with late-onset Wilson's disease: deterioration with penicillamine.
    Sohtaoglu M; Ergin H; Ozekmekçi S; Gökdemir S; Sonsuz A; Arici C
    Mov Disord; 2007 Jan; 22(2):290-1. PubMed ID: 17083099
    [No Abstract]   [Full Text] [Related]  

  • 31. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease.
    Hanukoglu A; Curiel B; Berkowitz D; Levine A; Sack J; Lorberboym M
    J Pediatr; 2008 Dec; 153(6):864-6. PubMed ID: 19014823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for a ternary complex containing albumin, copper, and penicillamine.
    Sugiura Y; Tanaka H
    Mol Pharmacol; 1972 Mar; 8(2):249-55. PubMed ID: 5063485
    [No Abstract]   [Full Text] [Related]  

  • 33. [Therapy of Wilson disease].
    Smolarek C; Stremmel W
    Z Gastroenterol; 1999 Apr; 37(4):293-300. PubMed ID: 10378366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zinc treatment for symptomatic Wilson disease: moving forward by looking back.
    Schilsky M
    Hepatology; 2009 Nov; 50(5):1341-3. PubMed ID: 19877301
    [No Abstract]   [Full Text] [Related]  

  • 35. [Wilson's disease treated with penicillamine (author's transl)].
    Aksamija-Rizvić B
    Lijec Vjesn; 1976 Aug; 98(8):430-1. PubMed ID: 1004094
    [No Abstract]   [Full Text] [Related]  

  • 36. [On hepatolenticular degeneration (Wilson's disease). 3. Hepatic localization of Cu64: scintigraphic and dynamic study before and after treatment with BAL and D-penicillamine].
    D'Addabbo A; Damato VD; Germinario L; Campanella G; Boccuni N
    Acta Neurol (Napoli); 1971; 26(4):436-48. PubMed ID: 5132825
    [No Abstract]   [Full Text] [Related]  

  • 37. [Westphal-Strumpell disease. Description of a clinical case].
    Nuccetelli F; Assetta M; Colangelo U; Gambi D
    Minerva Med; 1987 Sep; 78(17):1321-3. PubMed ID: 3670684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obliterating bronchiolitis in a patient treated with (D)-penicillamine.
    Bruguera-Àvila N; Sánchez-Martínez E; Garcia-Olivé I; Pérez-Ochoa JF; Martínez-Barenys C; Ruiz-Manzano J
    Arch Bronconeumol; 2013 Sep; 49(9):411-2. PubMed ID: 23582262
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of Wilson's disease with triethylene tetramine dihydrochloride. A case report.
    Haslam RH; Sass-Kortsak A; Stout W; Berg M
    Dev Pharmacol Ther; 1980; 1(5):318-24. PubMed ID: 7438976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mechanism for the action of penicillamine in the treatment of Wilson's disease.
    Peisach J; Blumberg WE
    Mol Pharmacol; 1969 Mar; 5(2):200-9. PubMed ID: 4306792
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.